Correction — August 27, 2026: An earlier version of this page incorrectly described CagriSema as semaphorin-related. CagriSema refers to cagrilintide plus semaglutide.
What CagriSema Means in Research Literature
CagriSema is the name used in published research for the combination of cagrilintide and semaglutide. Cagrilintide is a long-acting amylin analogue, while semaglutide is a GLP-1 receptor agonist. They are distinct molecular components.
The term CagriSema does not denote a semaphorin-derived peptide and should not be associated with semaphorin, plexin or neuropilin, axon-guidance, cytoskeletal-remodeling, or tissue-patterning pathways.
Catalog and documentation implications
Any catalog material described as a cagrilintide/semaglutide combination should identify the verified quantity or ratio of each component and provide lot-specific analytical evidence. A mixture generally should not be assigned one composite CAS number, molecular formula, or molecular weight; each verified component and chemical form should be reported separately.
Published literature about the named compounds does not establish the identity, purity, quantity, sterility, or stability of a BioVector lot.
Research references
For laboratory and research use only. Not for human or veterinary use. Not intended for consumption, diagnosis, treatment, prevention, or administration to humans or animals.